Interannual variability of photosynthesis across Africa and its attribution

Africa is thought to be a large source of interannual variability in the global carbon cycle, only vaguely attributed to climate fluctuations. This study uses a biophysical model, Simple Biosphere, to examine in detail what specific factors, physiological (acute stress from low soil water, temperature, or low humidity) and biophysical (low vegetation radiation use), are responsible for spatiotemporal patterns of photosynthesis across the African continent during the period 1982-2003. Acute soil water stress emerges as the primary factor driving interannual variability of photosynthesis for most of Africa. Southern savannas and woodlands are a particular hot spot of interannual variability in photosynthesis, owing to high rainfall variability and photosynthetic potential but intermediate annual rainfall. Surprisingly low interannual variability of photosynthesis in much of the Sudano-Sahelian zone derives from relatively low vegetation cover, pronounced humidity stress, and somewhat lower rainfall variability, whereas perennially wet conditions diminish interannual variability in photosynthesis across much of the Congo Basin and coastal West Africa. Though not of focus here, the coefficient of variation in photosynthesis is notably high in drylands and desert margins (i.e., Sahel, Greater Horn, Namib, and Kalahari) having implications for supply of food and fiber. These findings emphasize that when considering impacts of climate change and land surface feedbacks to the atmosphere, it is important to recognize how vegetation, climate, and soil characteristics may conspire to filter or dampen ecosystem responses to hydroclimatic variability. Copyright 2008 by the American Geophysical Union

Investigators share improved understanding of the North American Carbon Cycle

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/94828/1/eost16014.pd

An approach for verifying biogenic greenhouse gas emissions inventories with atmospheric CO₂ concentration data

Verifying national greenhouse gas (GHG) emissions inventories is a critical step to ensure that reported emissions data to the United Nations Framework Convention on Climate Change (UNFCCC) are accurate and representative of a country\u27s contribution to GHG concentrations in the atmosphere. Furthermore, verifying biogenic fluxes provides a check on estimated emissions associated with managing lands for carbon sequestration and other activities, which often have large uncertainties. We report here on the challenges and results associated with a case study using atmospheric measurements of CO₂ concentrations and inverse modeling to verify nationally-reported biogenic CO₂ emissions. The biogenic CO₂ emissions inventory was compiled for the Mid-Continent region of United States based on methods and data used by the US government for reporting to the UNFCCC, along with additional sources and sinks to produce a full carbon balance. The biogenic emissions inventory produced an estimated flux of −408 ± 136 Tg CO₂ for the entire study region, which was not statistically different from the biogenic flux of −478 ± 146 Tg CO₂ that was estimated using the atmospheric CO₂concentration data. At sub-regional scales, the spatial density of atmospheric observations did not appear sufficient to verify emissions in general. However, a difference between the inventory and inversion results was found in one isolated area of West-central Wisconsin. This part of the region is dominated by forestlands, suggesting that further investigation may be warranted into the forest C stock or harvested wood product data from this portion of the study area. The results suggest that observations of atmospheric CO₂ concentration data and inverse modeling could be used to verify biogenic emissions, and provide more confidence in biogenic GHG emissions reporting to the UNFCCC

Estimate of carbonyl sulfide tropical oceanic surface fluxes using Aura Tropospheric Emission Spectrometer observations

Quantifying the carbonyl sulfide (OCS) land/ocean fluxes contributes to the understanding of both the sulfur and carbon cycles. The primary sources and sinks of OCS are very likely in a steady state because there is no significant observed trend or interannual variability in atmospheric OCS measurements. However, the magnitude and spatial distribution of the dominant ocean source are highly uncertain due to the lack of observations. In particular, estimates of the oceanic fluxes range from approximately 280 Gg S yr^(−1) to greater than 800 Gg S yr^(−1), with the larger flux needed to balance a similarly sized terrestrial sink that is inferred from NOAA continental sites. Here we estimate summer tropical oceanic fluxes of OCS in 2006 using a linear flux inversion algorithm and new OCS data acquired by the Aura Tropospheric Emissions Spectrometer (TES). Modeled OCS concentrations based on these updated fluxes are consistent with HIAPER Pole‐to‐Pole Observations during 4th airborne campaign and improve significantly over the a priori model concentrations. The TES tropical ocean estimate of 70 ± 16 Gg S in June, when extrapolated over the whole year (about 840 ± 192 Gg S yr^(−1), supports the hypothesis proposed by Berry et al. (2013) that the ocean flux is in the higher range of approximately 800 Gg S yr^(−1)

To respond or not to respond - a personal perspective of intestinal tolerance

For many years, the intestine was one of the poor relations of the immunology world, being a realm inhabited mostly by specialists and those interested in unusual phenomena. However, this has changed dramatically in recent years with the realization of how important the microbiota is in shaping immune function throughout the body, and almost every major immunology institution now includes the intestine as an area of interest. One of the most important aspects of the intestinal immune system is how it discriminates carefully between harmless and harmful antigens, in particular, its ability to generate active tolerance to materials such as commensal bacteria and food proteins. This phenomenon has been recognized for more than 100 years, and it is essential for preventing inflammatory disease in the intestine, but its basis remains enigmatic. Here, I discuss the progress that has been made in understanding oral tolerance during my 40 years in the field and highlight the topics that will be the focus of future research

TGFβR signalling determines CD103⁺CD11b⁺ dendritic cell development in the intestine

CD103+CD11b+ dendritic cells (DCs) are unique to the intestine, but the factors governing their differentiation are unclear. Here we show that transforming growth factor receptor 1 (TGFβR1) has an indispensable, cell intrinsic role in the development of these cells. Deletion of Tgfbr1 results in markedly fewer intestinal CD103+CD11b+ DCs and a reciprocal increase in the CD103−CD11b+ dendritic cell subset. Transcriptional profiling identifies markers that define the CD103+CD11b+ DC lineage, including CD101, TREM1 and Siglec-F, and shows that the absence of CD103+CD11b+ DCs in CD11c-Cre.Tgfbr1fl/fl mice reflects defective differentiation from CD103−CD11b+ intermediaries, rather than an isolated loss of CD103 expression. The defect in CD103+CD11b+ DCs is accompanied by reduced generation of antigen-specific, inducible FoxP3+ regulatory T cells in vitro and in vivo, and by reduced numbers of endogenous Th17 cells in the intestinal mucosa. Thus, TGFβR1-mediated signalling may explain the tissue-specific development of these unique DCs

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

Estimate of carbonyl sulfide tropical oceanic surface fluxes using Aura Tropospheric Emission Spectrometer observations

Quantifying the carbonyl sulfide (OCS) land/ocean fluxes contributes to the understanding of both the sulfur and carbon cycles. The primary sources and sinks of OCS are very likely in a steady state because there is no significant observed trend or interannual variability in atmospheric OCS measurements. However, the magnitude and spatial distribution of the dominant ocean source are highly uncertain due to the lack of observations. In particular, estimates of the oceanic fluxes range from approximately 280 Gg S yr^(−1) to greater than 800 Gg S yr^(−1), with the larger flux needed to balance a similarly sized terrestrial sink that is inferred from NOAA continental sites. Here we estimate summer tropical oceanic fluxes of OCS in 2006 using a linear flux inversion algorithm and new OCS data acquired by the Aura Tropospheric Emissions Spectrometer (TES). Modeled OCS concentrations based on these updated fluxes are consistent with HIAPER Pole‐to‐Pole Observations during 4th airborne campaign and improve significantly over the a priori model concentrations. The TES tropical ocean estimate of 70 ± 16 Gg S in June, when extrapolated over the whole year (about 840 ± 192 Gg S yr^(−1), supports the hypothesis proposed by Berry et al. (2013) that the ocean flux is in the higher range of approximately 800 Gg S yr^(−1)

Genes Differentially Expressed in Conidia and Hyphae of Aspergillus fumigatus upon Exposure to Human Neutrophils

Aspergillus fumigatus is the most common etiologic agent of invasive aspergillosis in immunocompromised patients. Several studies have addressed the mechanism involved in host defense but only few have investigated the pathogen's response to attack by the host cells. To our knowledge, this is the first study that investigates the genes differentially expressed in conidia vs hyphae of A. fumigatus in response to neutrophils from healthy donors as well as from those with chronic granulomatous disease (CGD) which are defective in the production of reactive oxygen species.Transcriptional profiles of conidia and hyphae exposed to neutrophils, either from normal donors or from CGD patients, were obtained by using the genome-wide microarray. Upon exposure to either normal or CGD neutrophils, 244 genes were up-regulated in conidia but not in hyphae. Several of these genes are involved in the degradation of fatty acids, peroxisome function and the glyoxylate cycle which suggests that conidia exposed to neutrophils reprogram their metabolism to adjust to the host environment. In addition, the mRNA levels of four genes encoding proteins putatively involved in iron/copper assimilation were found to be higher in conidia and hyphae exposed to normal neutrophils compared to those exposed to CGD neutrophils. Deletants in several of the differentially expressed genes showed phenotypes related to the proposed functions, i.e. deletants of genes involved in fatty acid catabolism showed defective growth on fatty acids and the deletants of iron/copper assimilation showed higher sensitivity to the oxidative agent menadione. None of these deletants, however, showed reduced resistance to neutrophil attack.This work reveals the complex response of the fungus to leukocytes, one of the major host factors involved in antifungal defense, and identifies fungal genes that may be involved in establishing or prolonging infections in humans